A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Teva Identifier
TV48125-CNS-30082
ClinicalTrials.gov Identifier
NCT04464707
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo
EudraCT Number
2019-002053-33
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
headache-icon

Key Participation Requirements

Gender
Female, Male
Age group
Child
Age Range
6 Years to 17 Years
Trial Duration
September 24, 2020 - November 29, 2024
Phase
Phase 3

Additional info

Study Type

Interventional